Dapirolizumab pegol demonstrated significant efficacy in reducing fatigue and disease activity in systemic lupus erythematosus patients during the PHOENYCS GO study. Dapirolizumab pegol (DZP), a novel ...
UCB and Biogen (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, or DZP, a novel Fc-free anti-CD40L drug candidate, demonstrating significant ...
UCB and Biogen have announced positive Phase III clinical trial results for PHOENYCS GO study, evaluating dapirolizumab pegol, a new treatment for moderate-to-severe systemic lupus erythematosus (SLE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback